GH501a

GH501a is a preclinical small‑molecule anticancer candidate that was identified by Arch Biopartners as a lead compound from a University of Colorado–derived library based on positive preclinical efficacy in cell culture and mouse models of pancreatic, lung, and prostate cancer. It was proposed as a potential treatment for non‑small cell lung cancer and pancreatic cancer, with Intertek Cantox engaged to design a development plan, but Arch Biopartners chose not to exercise its option to license the underlying compounds and does not intend to further develop GH501a, leaving its precise molecular target, mechanism of action, structure, and pharmacology undisclosed in the public domain.[7][8][9]